Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis
BackgroundImmune checkpoint inhibitors (ICIs) have been proven to be an effective treatment strategy for a variety of malignant tumors. However, only a subset of patients can benefit from ICIs due to factors such as drug resistance. Therefore, it is crucial to identify biomarkers that can accurately...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1176574/full |
| _version_ | 1797746175952027648 |
|---|---|
| author | Dan Zou Ailin Song Wei Yong |
| author_facet | Dan Zou Ailin Song Wei Yong |
| author_sort | Dan Zou |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors (ICIs) have been proven to be an effective treatment strategy for a variety of malignant tumors. However, only a subset of patients can benefit from ICIs due to factors such as drug resistance. Therefore, it is crucial to identify biomarkers that can accurately predict the efficacy of ICIs and provide a basis for individualized immunotherapy. In this study, we conducted a systematic review and meta-analysis to explore whether the chemokine interleukin 8 (IL-8) can be used as a biomarker to evaluate the efficacy of ICIs treatment.MethodsWe conducted a comprehensive search of several databases, including PubMed, Embase, Web of Science, and Cochrane, to identify relevant articles published up to June 08, 2023. Our inclusion criteria were limited to cohort studies and clinical trials that reported hazard ratios (HR) and 95% confidence intervals (CI) for overall survival (OS) and/or progression-free survival (PFS), as well as the objective response rate (ORR), in cancer patients with high and low IL-8 expression. For data analysis, we used Revman to generate forest plots, subgroup analysis, and assess publication bias. Additionally, Stata was utilized for sensitivity analysis and further examination of publication bias.ResultsA total of 24 datasets, involving 3190 participants, were selected from 14 studies. The meta-analysis revealed a reduction in ORR, OS, and/or PFS in the high IL-8 group after treatment with ICIs compared to the low IL-8 group.ConclusionIL-8 can serve as a biomarker for predicting the efficacy of ICIs. Patients with lower expression of IL-8 may benefit from ICIs treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=383188, identifier CRD42022383188. |
| first_indexed | 2024-03-12T15:33:14Z |
| format | Article |
| id | doaj.art-427dfdcd68c54d419a6d1d4ebf50293f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-12T15:33:14Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-427dfdcd68c54d419a6d1d4ebf50293f2023-08-09T18:48:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-08-011310.3389/fonc.2023.11765741176574Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysisDan Zou0Ailin Song1Wei Yong2Thyroid & Breast Surgery, Chengdu Seventh People’s Hospital, Chengdu, Sichuan, ChinaThyroid & Breast Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu, ChinaThyroid & Breast Surgery, Chengdu Seventh People’s Hospital, Chengdu, Sichuan, ChinaBackgroundImmune checkpoint inhibitors (ICIs) have been proven to be an effective treatment strategy for a variety of malignant tumors. However, only a subset of patients can benefit from ICIs due to factors such as drug resistance. Therefore, it is crucial to identify biomarkers that can accurately predict the efficacy of ICIs and provide a basis for individualized immunotherapy. In this study, we conducted a systematic review and meta-analysis to explore whether the chemokine interleukin 8 (IL-8) can be used as a biomarker to evaluate the efficacy of ICIs treatment.MethodsWe conducted a comprehensive search of several databases, including PubMed, Embase, Web of Science, and Cochrane, to identify relevant articles published up to June 08, 2023. Our inclusion criteria were limited to cohort studies and clinical trials that reported hazard ratios (HR) and 95% confidence intervals (CI) for overall survival (OS) and/or progression-free survival (PFS), as well as the objective response rate (ORR), in cancer patients with high and low IL-8 expression. For data analysis, we used Revman to generate forest plots, subgroup analysis, and assess publication bias. Additionally, Stata was utilized for sensitivity analysis and further examination of publication bias.ResultsA total of 24 datasets, involving 3190 participants, were selected from 14 studies. The meta-analysis revealed a reduction in ORR, OS, and/or PFS in the high IL-8 group after treatment with ICIs compared to the low IL-8 group.ConclusionIL-8 can serve as a biomarker for predicting the efficacy of ICIs. Patients with lower expression of IL-8 may benefit from ICIs treatment.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=383188, identifier CRD42022383188.https://www.frontiersin.org/articles/10.3389/fonc.2023.1176574/fullinterleukin 8immune checkpoint inhibitorsprognostic rolebiomarkersmeta-analysis |
| spellingShingle | Dan Zou Ailin Song Wei Yong Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis Frontiers in Oncology interleukin 8 immune checkpoint inhibitors prognostic role biomarkers meta-analysis |
| title | Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis |
| title_full | Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis |
| title_fullStr | Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis |
| title_full_unstemmed | Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis |
| title_short | Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis |
| title_sort | prognostic role of il 8 in cancer patients treated with immune checkpoint inhibitors a system review and meta analysis |
| topic | interleukin 8 immune checkpoint inhibitors prognostic role biomarkers meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1176574/full |
| work_keys_str_mv | AT danzou prognosticroleofil8incancerpatientstreatedwithimmunecheckpointinhibitorsasystemreviewandmetaanalysis AT ailinsong prognosticroleofil8incancerpatientstreatedwithimmunecheckpointinhibitorsasystemreviewandmetaanalysis AT weiyong prognosticroleofil8incancerpatientstreatedwithimmunecheckpointinhibitorsasystemreviewandmetaanalysis |